Amgen Inc
Veridion Score
Composite trend over time
Why is AMGN moving today?
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
AMGN insider activity
Amgen Inc
11 insiders bought in the last 90 days
Net buying: $13.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | 2026-05-07 | Bradner James E. | Insider | sell | $331.11 | 446 | 30,016 | $148K | SEC Form 4 |
| 2026-05-11 | 2026-05-07 | Busch Matthew C. | Insider | sell | $331.11 | 41 | 4,344 | $14K | SEC Form 4 |
| 2026-05-11 | 2026-05-07 | Miller Derek | Insider | sell | $331.11 | 151 | 12,444 | $50K | SEC Form 4 |
| 2026-05-11 | 2026-05-07 | Khosla Rachna | Insider | sell | $331.11 | 93 | 8,394 | $31K | SEC Form 4 |
| 2026-05-11 | 2026-05-07 | Grygiel Nancy A. | Insider | sell | $331.11 | 88 | 7,330 | $29K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 78 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moAMGN contract awards, year to date.
Public federal awards linked to this ticker.
AMGN lobbying filings, year to date.
Registered lobbying filings matched to Amgen Inc.